Preferred Name: Gottfried E. Konecny
Gottfried E. Konecny is the lead clinician for gynecologic oncology in the Department of Medicine at UCLA. He obtained his medical degree and completed his residency training in obstetrics and gynecology at the University of Munich in Germany. Following his specialist training he focused on clinical breast cancer research and decided to move to the U.S. to pursue postdoctoral studies in the laboratory of Dennis J. Slamon to participate in laboratory and clinical research that led to the approval of new breast cancer drugs such as trastuzumab and lapatinib. He subsequently undertook research and subspecialty training in gynecologic oncology by completing a gynecologic oncology fellowship at Mayo Clinic in Rochester Minnesota. In 2007 he was recruited back to the University of California as a group leader to the Translational Oncology Research Laboratory of UCLA, to establish a laboratory for preclinical drug and clinical trial development in the area of gynecologic malignancies.
- Ovarian Cancer
- Endometrial Cancer
- Cervical Cancer
- Breast Cancer
Dr. Konecny's initiatives are primarily directed at using the latest and most effective technologies available to query ovarian, endometrial and cervical cancer tissues, combined with appropriately characterized and molecularly defined preclinical models to identify new alterations and/or understand the role of known alterations in relevant genes and molecular pathways. As a physician-scientist his work focuses on translating the incredible revolution in our understanding of the molecular underpinnings of cancer into novel treatment approaches, in which each patient is treated according to the specific genetic alterations of the tumor.
- Bojesen SE , Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edward SL, Pickett HA,..., Konecny GE,.... Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench, Dunning AM. Multiple independent TERT variants associated with telomere length and risks of breast and ovarian cancer. Nature Genetics 45(4):371-84, 2013
- Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginter C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong H, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE. Therapeutic Potential of the Poly (ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer. Molecular Cancer Ther 12(6):1002-15, 2013
- Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, Belmontes B, Li CM, Vonderfecht S, Velculescu VE, Yang G, Qi J, Slamon DJ, Konecny GE. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin Cancer Res 2014;20(11):2947-58
- Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest 2014;124(6):2611-25
- Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, Goode EL. Prognostic and Therapeutic Relevance of Molecular Subtypes in High Grade Serous Ovarian Cancer. J Natl Cancer Inst 2014;106 (10):dju249
- Konecny GE, Finkler N, Garcia AA, Lorusso D, Lee D, Rocconi R, Fong PC, Squires M, Mishra K, Upalawanna A, Wang Y, Kristeleit R. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomized, open-label, two-group, two-stage, phase 2 study. Lancet Oncol 2015;16(6):686-94.
- Winterhoff BJN, Hamidi H, Wang C, Kalli KR, Fridley, Dering J Chen HW, Cliby WA, Wang HJ, Dowdy SC, Gostout BS, Keeney GS, Goode EL, Konecny GE. Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expressions signatures. Gynecol Oncol 2016;141(1):95-100.
- Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncology 2017;18(1):75-87
- Kommoss S, Winterhoff B, Oberg A, Konecny GE, Wang C, Riska SM, Fan JB, Maurer MJ, April C, Shridhar V, Kommoss F, du Bois A, Hilpert F, Mahner S, Baumann K, Schroeder W, Burges A, Canzler U, Chien J, Embleton AC, Parmar M, Kaplan R, Perren T, Hartmann LC, Goode EL, Dowdy SC, Pfisterer J. Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clin Cancer Res 2017 [Epub ahead of print]
- Konecny GE. Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer. J Clin Oncol 2017;35(11):1151-1153
- Presidential Award Society of Gynecologic Oncology 2017
- STOP Cancer Research Award Los Angeles, California 2016
- Joe V. Meigs Award, Society of Pelvic Surgeons (SPS) 2014
- Elected Member of the Sudeto-German Academy of Sciences 2014
- UCLA Jonsson Cancer Center Award for Clinical Excellence 2012
- Scientific Program Committee, American Society of Clinical Oncology (ASCO) 2012-2015
- Habilitation - Ludwig Maximilians Universität 2002
- München, Germany